IBRANCE^® (palbociclib) combination therapy is now approved for maintenance treatment of HR+/HER2+ metastatic breast cancer

IBRANCE is a prescription medicine used for HER2-Positive Metastatic Breast Cancer as maintenance treatment in adults with HR-positive, HER2-positive breast cancer that has spread to nearby tissue or lymph nodes (locally advanced), or to other parts of the body (metastatic) in combination with trastuzumab, with or without pertuzumab, and hormonal therapy. Ask your healthcare provider for more information.

Learn more about IBRANCE combination therapy for HR+/HER2- mBC

Continue to IBRANCE

HR=hormone receptor; HR+=hormone receptor-positive; HER2=human epidermal growth factor receptor 2; HER2+=human epidermal growth factor receptor 2-positive; mBC=metastatic breast cancer.